Resumen: Alnylam presentará nuevos análisis en Heart Failure 2026 que refuerzan la consistencia del perfil clínico de vutrisirán en la ATTR-CM

Key Takeaway: Alnylam plans to present new analyses at Heart Failure 2026 that support the clinical profile consistency of vutrisiran in ATTR-CM. The details of these analyses are currently limited, but they aim to reinforce the therapeutic potential of vutrisiran in treating this condition.